Clinical trials: Acute Allergic Reaction
Status Asthmaticus
Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation
The purpose of this study is to investigate whether heliox-powered albuterol nebulizer therapy will result in reduced inpatient length of stay in children hospitalized with acute asthma exacerbations.
- Trial name
- NCT00410150
- Testing
- Helium-oxygen-driven albuterol nebulizer, Oxygen
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
This is a phase I study using the Erwinia form of asparaginase in place of the E. coli form using a standard re-induction regimen (Vincristine, Dexamethasone, Doxorubicin) for patients with relapsed ALL who have developed an…
- Conditions
- Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase
- Trial name
- NCT00928200
- Testing
- Erwinase, Vincristine, Dexamethasone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Acute Coronary Syndrome
Early Risk Stratification in ED Chest Pain Patients
In the management of adult chest pain patients presenting to an Emergency Department (ED) with suspected acute coronary syndrome (ACS), we aimed to evaluate the diagnostic accuracy of the combined use of a modified Thrombolysis…
- Trial name
- NCT02364271
- Testing
- Thrombolysis in myocardial infarction score, routine blood test for hs-cTnT, HEART score
- Where
- China
- Volunteers
- 602 people
- Sponsor
- Chinese University of Hong Kong
Common Cold, Allergy
Symbiofilm Trial in Allergic Kids (SYMBIOFILM-TAK)
Healsea® Children is a seawater-based nasal spray supplemented with a natural Symbiofilm® extract (0.02%) isolated from marine bacteria.
- Trial name
- NCT05034328
- Testing
- Healsea® Children, Conventional therapies for common cold
- Where
- 15 sites in Poland
- Volunteers
- 186 people
- Sponsor
- Lallemand Pharma AG
Hereditary Angioedema
Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)
Primary Outcome Measures: The primary endpoint was the time to onset of symptom relief of the first attack in the double blind phase.
- Trial name
- FAST2 (NCT00500656)
- Testing
- Icatibant, Tranexamic Acid
- Where
- Italy
- Volunteers
- 85 people
- Sponsor
- Shire
Acute Coronary Syndrome, Fear Anxiety
The Reducing Exercise Sensitivity With Exposure Training (RESET) Study
This study investigates the feasibility of conducting a home-based reducing exercise sensitivity with exposure training (RESET) intervention among acute coronary syndrome (ACS) survivors.
- Conditions
- Acute Coronary Syndrome, Fear Anxiety, Physical Inactivity
- Trial name
- RESET (NCT05099926)
- Testing
- Reducing Exercise Sensitivity with Exposure Training
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Asthma
Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide
Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma membrane-mediated and do not require gene transcription and translation.
- Trial name
- NCT01219738
- Testing
- Budesonide 360ug, Budesonide 720ug, Budesonide 1440ug
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Miami
Pediatric, Asthma, Acute Exacerbation, Pediatric ICU
Use of High Frequency Chest Compression in Pediatric Status Asthmaticus
Asthma is a disease resulting in mucus hypersecretion and airways obstruction. This causes difficulty breathing. The High Frequency Chest Compressor (HFCC) is a device that has been shown to decrease respiratory complications in…
- Trial name
- NCT00552448
- Testing
- High Frequency Chest Compression VEST
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Texas Tech University Health Sciences Center
Allergic Conjunctivitis
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
To evaluate the efficacy and safety of two concentrations of PRT-2761 as a topical ophthalmic solution for the treatment of the signs and symptoms of acute and chronic allergic conjunctivitis.
- Trial name
- NCT03320434
- Testing
- PRT-2761 0.5%, PRT-2761 1%, Patanol
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- ORA, Inc.
Hereditary Angioedema, Hereditary Angioedema Type I
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE).
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
- Trial name
- RAPIDe-1 (NCT04618211)
- Testing
- Deucrictibant
- Where
- 36 sites in United States, Bulgaria and 11 more
- Volunteers
- 74 people
- Sponsor
- Pharvaris Netherlands B.V.
Hereditary Angioedema (HAE)
Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
This 3-part study will evaluate the efficacy and safety of an oral kallikrein inhibitor, BCX7353, in the treatment angioedema attacks in subjects with Type I or II hereditary angioedema (HAE).
- Trial name
- NCT03240133
- Testing
- BCX7353
- Where
- 24 sites in Austria, Denmark and 10 more
- Volunteers
- 58 people
- Sponsor
- BioCryst Pharmaceuticals
Asthma
A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).
The study will evaluate the effect of two intravenous dose regimens of benralizumab (MEDI-563) on the proportion of adult subjects with asthma exacerbations who required an urgent healthcare visit for treatment of an acute asthma…
- Trial name
- NCT00768079
- Testing
- Benralizumab
- Where
- 11 sites in United States, Canada
- Volunteers
- 110 people
- Sponsor
- MedImmune LLC
SARS-CoV Infection, COVID-19
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Background: Allergic reactions have been reported to occur after vaccination with both the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine.
- Conditions
- SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
- Trial name
- SARS (NCT04761822)
- Testing
- Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine
- Where
- 29 sites in United States
- Volunteers
- 746 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hereditary Angioedema
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
The study objective was to evaluate the safety and efficacy of repeat use of C1INH-nf for the treatment of acute HAE attacks.
- Trial name
- CHANGE 2 (NCT00438815)
- Testing
- C1 esterase inhibitor [human] (C1INH-nf)
- Where
- 30 sites in United States
- Volunteers
- 113 people
- Sponsor
- Shire
Hereditary Angioedema (HAE)
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
The objectives of this study were to evaluate: (1) the dose response and (2) the pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous (IV) administration of CINRYZE for the treatment of acute angioedema attacks in…
- Trial name
- NCT01095510
- Testing
- CINRYZE
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 9 people
- Sponsor
- Shire
Allergic Conjunctivitis
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01881113
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Epilepsy
Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.
- Trial name
- ARTEMIS1 (NCT01390220)
- Testing
- USL261
- Where
- 90 sites in United States, Australia and 9 more
- Volunteers
- 292 people
- Sponsor
- UCB Biopharma S.P.R.L.
Sickle Cell Disease, Anemia, Sickle Cell
Daily Vitamin D for Sickle-cell Respiratory Complications
This study aims to answer the question whether daily oral vitamin D supplementation can reduce the risk of respiratory or lung complications in children and adolescents with sickle cell disease.
- Conditions
- Sickle Cell Disease, Anemia, Sickle Cell, Anemia, Hemolytic, Congenital, Respiratory Tract Diseases
- Trial name
- ViDAS-2 (NCT04170348)
- Testing
- Daily oral vitamin D3, 3,333 IU, Monthly oral vitamin D3, 100,000 IU
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Columbia University
Migraine
A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine
This is a research study looking at Migranal (study drug) in the treatment of two migraine attacks in patients who have a history of cutaneous allodynia (pronounced q-tay-nee-us al-o-din-ee-a).
- Trial name
- NCT00335777
- Testing
- Migranal nasal spray at 1 hour, Migranal nasal spray at 4 hour
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Thomas Jefferson University
Hereditary Angioedema
Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
This open-label study is being conducted to confirm the safety, pharmacokinetic profile and efficacy of Ruconest at a dose of 50 U/kg when used for the treatment of acute angioedema attacks in patients, from 2 up to and including…
- Trial name
- NCT01359969
- Testing
- rhC1INH
- Where
- 16 sites in United States, Czechia and 8 more
- Volunteers
- 57 people
- Sponsor
- Pharming Technologies B.V.